We have so many great drugs to treat CLL. How to sequence them is unclear, but Dr. Mato presents some reassuring data that when we use venetoclax, namely that we still have some good options when it stops working in this interview from ASH 2019 (cllsociety.org/2020/02/ash-....
CLLAN is an international “umbrella” charity organization helps CLL charities in Europe and the 3rd world that the CLL Society proudly supports. Learn more here (cllsociety.org/about-us/cll....
Stay strong.
We are all in this together.
Brian
Brian Koffman MDCM (retired) MS Ed
Co-Founder, Executive VP and Chief Medical Officer
Thanks as always Dr. Koffman. I liked the interview with Dr. Mato and appreciated when you stopped him so as to clarify some of the terms he used so that others could comprehend his information more clearly.
Brian, I'm currently on the I V trial at MDA. I reached 0.01% MRD at 15mos in the blood, same as I was at 12 mos. My bone marrow at 12 mos was 0.02%. Even if I reach UMRD4 at 18 mos I'm considering staying on Ibrutinib continuously after the trial. My reasons are that I also found out during this trial that I have 4-39 genes usage and a little ( less that 10%) notch 1 which put me at a higher risk for RT. So I think if the I V got me down this far on MRD, the Ibrutinib alone might be able to keep me there and at those low levels lessen my chance of Richters. I don't want to break treatment with Ibrutinib because it might increase the chance of resistance. So far no one has OKed this, but they haven't said no either.
Content on HealthUnlocked does not replace the relationship between you and doctors or other healthcare professionals nor the advice you receive from them.
Never delay seeking advice or dialling emergency services because of something that you have read on HealthUnlocked.
